Literature DB >> 25694749

Evaluation of serum amyloid a as a marker of persistent inflammation in patients with rheumatoid arthritis.

Mehmet Agilli1, Fevzi Nuri Aydin2, Tuncer Cayci3, Yasemin Gulcan Kurt3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25694749      PMCID: PMC4324919          DOI: 10.1155/2015/843152

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


× No keyword cloud information.
We read with great interest the paper by Targońska-Stępniak and Majdan titled “Serum Amyloid A as a Marker of Persistent Inflammation and an Indicator of Cardiovascular and Renal Involvement in Patients with Rheumatoid Arthritis” in which the investigators reported that high serum amyloid A (SAA) concentration was strongly associated with activity of the disease and risk of cardiovascular and renal involvement in patients with rheumatoid arthritis [1]. We thank the authors for their detailed report. However, we wish to make some comments on SAA. SAA is produced in the liver in response to proinflammatory cytokines such as tumor necrosis factor alpha (TNF-α), interleukin-1 (IL-1), and IL-6 [2]. Previous studies suggested that several diseases such as ankylosing spondylitis, autoinflammatory diseases (Hashimoto's thyroiditis, familial Mediterranean fever), major depression, systemic lupus erythematosus, diabetes mellitus, inflammatory bowel diseases, acute pancreatitis, several types of vasculitis, psoriasis, and epilepsy could affect SAA levels [3, 4]. In addition to these diseases, glucocorticoids, statins, disease-modifying antirheumatic drugs, corticosteroids, and nonsteroidal anti-inflammatory drugs could alter SAA levels [5, 6]. Also, dietary food supplements such as antioxidants (ascorbic acid, taurine, and phytic acid), vitamin E, vitamin A, α linoleic acid, omega-3 fatty acids, and polyunsaturated fatty acids can influence SAA levels [7, 8]. In this respect, without defining these contributing factors, interpreting the results is problematic. Alcohol use and smoking status of participants are other confounding factors for SAA measurement [9, 10]. Therefore, these factors have to be expressed and a multivariate regression analysis should be applied to show whether these variables have an impact on SAA levels. In conclusion, clarifying these concerns will certainly provide a clearer picture when interpreting SAA levels among participants.
  10 in total

Review 1.  Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview.

Authors:  Laura Obici; Sara Raimondi; Francesca Lavatelli; Vittorio Bellotti; Giampaolo Merlini
Journal:  Arthritis Rheum       Date:  2009-10-15

2.  Statin therapy reduces inflammatory markers in hypercholesterolemic patients with high baseline levels.

Authors:  Yuki Horiuchi; Satoshi Hirayama; Satoshi Soda; Utako Seino; Mika Kon; Tsuyoshi Ueno; Mayumi Idei; Osamu Hanyu; Takashi Tsuda; Hirotoshi Ohmura; Takashi Miida
Journal:  J Atheroscler Thromb       Date:  2010-06-02       Impact factor: 4.928

3.  Human serum amyloid A (SAA) protein changes in acute epilepsy patients.

Authors:  Guifen Li; Fang Ren; Jinhua Yao; Mingying Wang; Xianjun Feng; Dong Liu
Journal:  Int J Neurosci       Date:  2013-01-29       Impact factor: 2.292

Review 4.  The effects of diet on inflammation: emphasis on the metabolic syndrome.

Authors:  Dario Giugliano; Antonio Ceriello; Katherine Esposito
Journal:  J Am Coll Cardiol       Date:  2006-07-24       Impact factor: 24.094

5.  An explanation for the paradoxical induction and suppression of an acute phase response by ethanol.

Authors:  Brandon S Pruett; Stephen B Pruett
Journal:  Alcohol       Date:  2006-10-02       Impact factor: 2.405

6.  Severe protein losing enteropathy with intractable diarrhea due to systemic AA amyloidosis, successfully treated with corticosteroid and octreotide.

Authors:  Tomohisa Fushimi; Yasuhumi Takahashi; Yuichiro Kashima; Kazuhiro Fukushima; Wataru Ishii; Kazuma Kaneko; Masahide Yazaki; Akinori Nakamura; Takahiko Tokuda; Masayuki Matsuda; Ryo Furuya; Shu-Ichi Ikeda
Journal:  Amyloid       Date:  2005-03       Impact factor: 7.141

7.  Serum amyloid-A protein and serum rheumatoid factor as serological surrogate markers for smoking risk factor in Saudi population.

Authors:  Abdulbasit Ibraheem Al-Sieni; Adel Ibraheem Al-Alawy; Zafer Saad Al-Shehri; Fahad Ahmed Al-Abbasi
Journal:  Pak J Pharm Sci       Date:  2013-03       Impact factor: 0.684

8.  Serum amyloid A as a marker of persistent inflammation and an indicator of cardiovascular and renal involvement in patients with rheumatoid arthritis.

Authors:  Bożena Targońska-Stępniak; Maria Majdan
Journal:  Mediators Inflamm       Date:  2014-11-27       Impact factor: 4.711

Review 9.  Recent insights into the pathogenesis of type AA amyloidosis.

Authors:  J C H van der Hilst
Journal:  ScientificWorldJournal       Date:  2011-03-07

10.  Antioxidants inhibit SAA formation and pro-inflammatory cytokine release in a human cell model of alkaptonuria.

Authors:  Adriano Spreafico; Lia Millucci; Lorenzo Ghezzi; Michela Geminiani; Daniela Braconi; Loredana Amato; Federico Chellini; Bruno Frediani; Elena Moretti; Giulia Collodel; Giulia Bernardini; Annalisa Santucci
Journal:  Rheumatology (Oxford)       Date:  2013-05-23       Impact factor: 7.580

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.